Neurology: Volume 92, Number 18, April 30, 2019 Exam #1 - Safety, tolerability, and efficacy of fluoxetine as an antiviral for acute flaccid myelitis
About this course
- Released: 04/30/2019
- Expires: 04/30/2022
SAFETY, TOLERABILITY, AND EFFICACY OF FLUOXETINE AS AN ANTIVIRAL FOR ACUTE FLACCID MYELITIS
Upon completion of the article by Messacar et al, the participant should be able to:
- Discuss the in vitro mechanism by which fluoxetine inhibits the viral life cycle
- State approximately what percentage of patients had a prodromal illness preceding acute flaccid myelitis (AFM) symptom onset in this study
- Summarize what was found in this study regarding tolerability and efficacy of fluoxetine treatment for AFM
The article by Messacar et al covers the following core competency:
- Medical Knowledge
Refer to listing above the references in each article.
THIS PAGE IS REQUIRED READING BEFORE BEGINNING ALL ACCME-ACCREDITED COURSES
The American Academy of Neurology Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
MISSION STATEMENT/PROGRAM OBJECTIVES
After evaluating a specific article published in Neurology, participants in the CME activity should be able to demonstrate an increase in, or affirmation of, their knowledge of clinical medicine. Participants should be able to evaluate the appropriateness of the clinical information as it applies to the provision of patient care.
This program is designed for physicians who are involved in providing patient care and who wish to advance their current knowledge of clinical medicine.
AMA CREDIT DESIGNATION STATEMENT
The American Academy of Neurology Institute designates this journal-based-CME activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
James WM Owens Jr. MD, PhD receives royalties from UpToDate, Waltham, MA; grant support from NIH (PI, K08NS054882); and a stipend in his editorial capacity for Neurology. Adam Kelly, MD, has served as a guest editor of Continuum (April 2014) and receives a stipend in his editorial capacity for Neurology.
This CME program receives no commercial support.